Abstract

Ampicillin (ABPC) was encapsulated within n-butylcyanoacrylate by using dextran 70K, glucose, or the both mixtures as polymerization stabilizer, and many ABPC-nanocapsules with the various physicochemical properties were probed with the antibacterial activity against methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), β-lactamase producing MRSA (blaZ gene) and β-lactamase non-producing MRSA (no blaZ gene), and other germs. Morphological changes of MSSA and MRSA were assessed by scanning electron microscopy. The released ABPC was measured at various time points (1, 3, 6 or 24 h). Nanoencapsulation with ABPC resulted in an incremental increase in the antibacterial activity against MRSA penicillinase producing and non-producing strains. The nanocapsule was adhered on the cell wall of MRSA, and the morphological change was characteristically found on scanning electron microscope (SEM) image. The nanocapsulation of ABPC by n-butylcyanoacrylate was reinforced against β-lactamase producing and also non-producing strains of methicillin-resistant Staphylococcus aureus, and it will be a highly efficient treatment for infections caused by β-lactamase non-producing MRSA strains.

Key words:  ABPC-nanocapsules; n-butylcyanoacrylate; β-lactamase non-producing MRSA.